Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.20 +0.40%

+$0.09 today

Market cap
$2.92B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 1.27M

Average 1.84M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$555.34M

FY 2025 · Annual

Net Income

-$512.54M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.66M108.46M330.53M00
Cost of Revenue000011.18M
Gross Profit48.66M108.46M330.53M0(11.18M)
Gross Margin100.0%100.0%100.0%——
Research & Development265.35M358.73M423.88M396.44M418.78M
Selling, General & Admin79.06M90.48M103.35M105.44M97.1M
Operating Expenses344.41M449.21M527.23M487.34M544.16M
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
EBITDA(282.56M)(315.59M)(128.47M)(492.89M)(497.63M)
EBITDA Margin-580.7%-291.0%-38.9%——
Operating Income(295.75M)(340.74M)(196.7M)(487.34M)(555.34M)
Operating Margin-607.8%-314.2%-59.5%——
Interest Income4.6M14.77M51.51M64.64M42.9M
Interest Expense00000
Other Income / Expenses4.6M14.77M51.51M64.64M42.9M
Income Before Tax(291.16M)(325.97M)(145.19M)(422.71M)(512.44M)
Pre-Tax Margin-598.3%-300.5%-43.9%——
Income Tax Expense(575K)21K30K68K102K
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Net Margin-597.2%-300.6%-43.9%——
EPS (Basic)(2.39)(2.60)(1.06)(2.57)(2.97)
EPS (Diluted)(2.39)(2.60)(1.06)(2.57)(2.97)
Weighted Avg Shares121.52M125.53M137.37M164.47M175.46M
Weighted Avg Shares (Diluted)121.52M125.53M137.37M164.47M175.46M

DNLI Earnings Waterfall · TTM

NASDAQ:DNLI · Revenue to Net Income

Key Ratios

EPS$-2.84
Gross Margin24.4%
Net Margin-884.8%
P/E Ratio-6.7
P/S Ratio334.2

Analysis

$3.6M of revenue converted into -$511.5M of net income for the selected period. Gross margin is 24.4% and net margin is -884.8%, showing how much revenue survives after costs and taxes. EPS is $-2.84, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipSep 9, 2026
4Statement of changes in beneficial ownershipSep 4, 2026
4Statement of changes in beneficial ownershipSep 3, 2026

How much revenue does DNLI generate?

Denali Therapeutics Inc. (DNLI) reported $0.00 of revenue in fiscal 2025.

Is DNLI profitable?

Denali Therapeutics Inc. (DNLI) reported -$512.54M of net income.